Radical concurrent chemoradiotherapy for esophageal carcinoma / 国际肿瘤学杂志

In National Comprehensive Cancer Network guideline, patients with the clinical stages of Ⅰ B-ⅢA esophageal neoplasms should be given radical PF regimen (cisplatin + 5-fluorouracil) concurrent chemoradiotherapy.The majorization PF and radiation dosage are studied by some scholars in China and abroad, and the local control rate and survival rate are improved, adverse reaction is within a controllable range.In recent years, some new drugs such as capecitabine, paclitaxel, docetaxel, pemetrexed and carboplatin also show their advantages in radical concurrent chemoradiotherapy.